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Introduction
============

The use of unfractionated heparin during percutaneous coronary intervention is limited by its unpredictable effect, the need for close monitoring, and the uncertainty around optimal levels of activated clotting time.[@ref1] [@ref2] [@ref3] [@ref4] Moreover, the drug exhibits prothrombotic properties related to platelet activation, poor control of von Willebrand factor release, and rebound of thrombin generation after discontinuation.[@ref5] [@ref6] Despite these limitations and the absence of relevant randomised placebo controlled trials, anticoagulation during elective and primary percutaneous coronary intervention has traditionally been supported by unfractionated heparin, based largely on historical practice. The current updated guidelines for anticoagulation in patients requiring percutaneous coronary intervention for ST segment elevation myocardial infarction produced by the American College of Cardiology, American Heart Association, and Society of Cardiac Angiography and Intervention as well as guidelines from the Task Force on Myocardial Revascularization of the European Society of Cardiology continue to afford unfractionated heparin a class 1 recommendation for this indication, despite limited supporting evidence (level of evidence C).[@ref7] [@ref8]

Enoxaparin is the leading low molecular weight heparin with the largest volume of published information on use in the setting of percutaneous coronary intervention. It provides predictable anticoagulation without the need for monitoring[@ref9] [@ref10] and it can be administered predominantly by subcutaneous injection, as in the management of non-ST elevation acute coronary syndromes and ST elevation myocardial infarction treated with thrombolysis, in both cases with a scheduled invasive strategy (American College of Cardiology and American Heart Association class IIa and I, respectively). Enoxaparin can also be used with intravenous injections for immediate anticoagulation in patients undergoing primary percutaneous coronary intervention or elective percutaneous coronary intervention, as shown recently in several randomised studies.[@ref11] [@ref12] [@ref13] [@ref14] Although studies have evaluated enoxaparin during percutaneous coronary intervention in several clinical settings,[@ref15] [@ref16] [@ref17] [@ref18] [@ref19] [@ref20] [@ref21] [@ref22] [@ref23] [@ref24] [@ref25] [@ref26] [@ref27] [@ref28] [@ref29] [@ref30] [@ref31] [@ref32] [@ref33] none was powered for mortality.

We pooled the data from all the studies that compared enoxaparin with unfractionated heparin during percutaneous coronary intervention to gain sufficient power to evaluate potential differences in mortality and safety.

Methods
=======

Two researchers (JS and GM) searched PubMed and the Cochrane database of systematic reviews from January 1996 to May 2011 using the search terms "enoxaparin", "unfractionated heparin", "angioplasty", and "percutaneous coronary intervention". In addition, we contacted experts in the specialty and reviewed abstracts from selected major cardiology scientific meetings (American Heart Association, American College of Cardiology, European Society of Cardiology, and Transcatheter Cardiovascular Therapeutics). The meta-analysis included cohort studies and clinical trials that compared the efficacy and safety of enoxaparin with unfractionated heparin among patients undergoing primary, secondary (post-fibrinolysis), or scheduled percutaneous coronary intervention according to a predefined protocol. We restricted our analysis to trials that met all of the following inclusion criteria: patients with coronary heart disease undergoing percutaneous coronary intervention, considering the whole study population or at least a predominant subset of this population; a control group using unfractionated heparin for comparison with enoxaparin; and publications reporting data at least on mortality and major bleeding. To focus on the direct comparison of enoxaparin with unfractionated heparin, we excluded studies that used a low molecular weight heparin other than enoxaparin, with the exception of one study in which other low molecular weight heparins were used in a few of the patients.[@ref34]

A total of 229 studies were identified as potentially relevant and were screened for inclusion. Of the 34 studies that fulfilled the inclusion criteria and were screened in detailed, we subsequently excluded 11 because they did not include data on efficacy outcomes[@ref35] did not include data on the percutaneous coronary intervention subgroup,[@ref36] [@ref37] [@ref38] [@ref39] [@ref40] [@ref41] published details of the percutaneous coronary intervention subgroup in a separate article,[@ref42] [@ref43] or studied a low molecular weight heparin other than enoxaparin.[@ref44] [@ref45] From the 23 studies remaining for the analysis, two reviewers (JS and OB) independently extracted outcome data and recorded the information on a standardised case report form. When available we extracted the following data from each trial: year of publication, trial design, population characteristics, number of patients (per group), dose and mode of enoxaparin administered, dose of unfractionated heparin, use of antiplatelet drugs (aspirin, thienopyridine, and platelet glycoprotein IIb/IIIa inhibitors), duration of follow-up, efficacy end points, and safety end points (see web extra table).

Assessment and reporting risk of bias in included studies
---------------------------------------------------------

Two independent reviewers determined the quality score of non-randomised studies and subanalysis and retrospective analysis of randomised controlled trials according to the Newcastle-Ottawa scale for cohort studies ([www.ohri.ca/programs/clinical_epidemiology/oxford.htm](http://www.ohri.ca/programs/clinical_epidemiology/oxford.htm)). We also carried out a validity assessment according to the Cochrane Collaboration's tool for assessing risk of bias. Randomised clinical trials were graded based on sequence generation, allocation concealment, blinding, incomplete outcome data, selective outcome reporting, and other sources of bias. For each trial we summarised the global assessment of risk of bias as low, unclear, or high. We entered data into a centralised database for analysis and resolved discrepancies by consensus of two authors (JS and OB). If additional data or clarification was necessary we contacted the study authors. When necessary, research associates with the relevant language helped to interpret non-English manuscripts.[@ref24]

Endpoint definitions
--------------------

The main objective of this study was to evaluate the impact of enoxaparin and unfractionated heparin on mortality (main efficacy end point) and major bleeding (main safety end point) during percutaneous coronary intervention. We considered all cause mortality except in studies where only cardiovascular mortality was reported. The bleeding definitions used for this analysis were those corresponding to the main safety end point of each study (see web extra table). Other efficacy end points analysed were the composite ischaemic end point of death or myocardial infarction and complications of myocardial infarction (or post-procedure myocardial infarction when this was the only reported complication) as defined in each study. Major bleeding was the main safety end point, although we also collected and analysed data on minor bleeding. We considered all end points at the longest follow-up available in each study. Firstly, we carried out a global meta-analysis of all the studies, including all patients after percutaneous coronary intervention regardless of the clinical presentation. Secondly, we carried out a meta-analysis for the same end points, restricting the analyses to predefined types of percutaneous coronary intervention: primary, secondary (post-fibrinolysis), and scheduled (patients with non-ST elevation acute coronary syndromes or stable patients).

Statistical analysis
--------------------

From each publication we obtained the raw numbers of patients experiencing the outcomes of interest among all patients in each treatment group. We obtained the common effect calculation by analysis of all patients. Using a random model we carried out several analyses to obtain a global estimation of the treatment effect and to minimise heterogeneity between groups. We used the EasyMa software (Department of Clinical Pharmacology and Biostatistic, EA643, university hospital of Lyon, France) to calculate relative risks with 95% confidence intervals.[@ref46] An α risk of 5% was used. Finally, the number of patients needed to treat (NNT) to avoid one event was calculated using the overall weighted risk difference: NNT=1/(absolute risk difference).

Confirmatory evaluation of potential bias
-----------------------------------------

We carried out a confirmatory analysis using the "meta" package of R software (R version 2.13.0, R Foundation for Statistical Computing) and arcsine transformation. This analysis accounts for heterogeneity, particularly when effect sizes are small and heterogeneity is high, and allows inclusion of trials with zero events in each arm.

Subgroup analysis and investigation of heterogeneity
----------------------------------------------------

Although the random effect model accommodated variability among studies, we examined the extent of heterogeneity in the individual trials. We used the Q Cochran test to look for heterogeneity between groups, with heterogeneity tests set at 0.1.[@ref47] Potential small study bias or publication bias (that is, the likelihood of small yet nominally significant studies being published selectively) was examined by visual inspection of constructed funnel plots and analytically using Egger's test.[@ref48] Egger's method plots linearly the standard normal deviate (natural logarithm of relative risk/standard error (SE) of relative risk) and precision (1/SE of relative risk) as independent variables, with test results based on the P value of the regression constant.

Sensitivity analysis
--------------------

We carried out a sensitivity analysis by removing each study in turn from the overall data to evaluate the influence of a single study on the pooled analysis and by restricting the meta-analysis to several subgroups: patients with ST elevation myocardial infarction undergoing percutaneous coronary intervention (primary or secondary), published (full length) studies, small (\<500 patients) versus large studies (≥500 patients), intravenous versus subcutaneous enoxaparin, and high quality (randomised controlled trials) or low quality studies (registry based).

Results
=======

Twenty three trials, totalling 30 966 patients, met the inclusion criteria (fig 1[](#fig1){ref-type="fig"}). Twelve randomised controlled trials and 11 non-randomised trials (including four subanalyses of randomised controlled trials) compared enoxaparin with unfractionated heparin during percutaneous coronary intervention. The average follow-up of the studies was 2.4 months, but most (n=19) had only short term follow-up (in hospital or at 30 days). A total of 13 943 patients (45.0%) received enoxaparin and 17 023 (55.0%) unfractionated heparin. In seven trials, totalling 10 243 patients (33.1%), primary percutaneous coronary intervention was carried out for ST elevation myocardial infarction; in three trials, totalling 8750 patients (28.2%), percutaneous coronary intervention was carried out after initial reperfusion with lytics; and in 13 trials, totalling 11 973 patients (38.7%), percutaneous coronary intervention was carried out in an elective setting. In 15 of these trials, enoxaparin was used as an intravenous bolus just before percutaneous coronary intervention; at a low dose (0.5 mg/kg) in four studies and at a higher dose (0.75 mg/kg or 1 mg/kg) in 12 studies (including the 0.75 mg/kg arm of the STEEPLE trial). In six trials, patients underwent percutaneous coronary intervention under a regimen of enoxaparin administered subcutaneously, and in two trials[@ref20] [@ref33] no mention was made of the enoxaparin dose or mode in which it was administered. The dose range for unfractionated heparin was 60 to 100 IU/kg bolus according to the concomitant use of platelet glycoprotein IIb/IIIa inhibitors or not, with further adjustments based on measurement of activated clotting time. Table 1[](#tbl1){ref-type="table"} outlines the details of the trials, the settings of the percutaneous coronary intervention, and length of follow-up (see web extra table for anticoagulation protocols, concomitant use of antiplatelet therapies, and major baseline characteristics of each study). Within each randomised trial, the baseline characteristics of patients treated with enoxaparin or with unfractionated heparin were similar, but some of the main characteristics in the registry based studies differed (see web extra table).

![**Fig 1** Flow of studies through review](silj003078.f1_default){#fig1}

###### 

 Description of studies included in meta-analysis

  Study                      Journal                                           No of patients in enoxaparin/unfractionated heparin groups   Study design (quality score\*or risk of bias)                 Study population/PCI setting                                                Follow-up
  -------------------------- ------------------------------------------------- ------------------------------------------------------------ ------------------------------------------------------------- --------------------------------------------------------------------------- -------------
  ATOLL 2011^14^             *Lancet*                                          450/460                                                      Randomised controlled trial (low risk)                        Primary PCI (STEMI)                                                         1 month
  Brieger et al 2011^16^     *Catheter Cardiovascular Intervention*            346/234                                                      Registry (8/9)                                                Primary PCI (STEMI)                                                         1 month
  Li et al 2010^28^          *American Heart Journal*                          1531/1841                                                    Registry (9/9)                                                Primary PCI (STEMI)                                                         8 months
  FINESSE Enox 2010^13^      *JACC. Cardiovascular Interventions*              759/1693                                                     Prospective substudy of randomised controlled trial (9/9)     Primary PCI (STEMI) with 33% of patients receiving half dose thrombolysis   3 months
  Galeote et al 2009^19^     *Medicina Intensiva*                              91/100                                                       Registry (6/9)                                                Primary PCI (STEMI)                                                         In-hospital
  Khoobiar et al 2008^29^    *Journal of Thrombosis and Thrombolysis*          39/44                                                        Registry (6/9)                                                Primary PCI (STEMI)                                                         15 months
  Zeymer et al 2008^43^      *Eurointervention*                                374/2281                                                     Registry (9/9)                                                Primary PCI (STEMI)                                                         In-hospital
  ExTRACT-TIMI 25 2007^34^   *Journal of the American College of Cardiology*   2272/2404                                                    Retrospective analysis of randomised controlled trial (9/9)   Post-fibrinolysis PCI (STEMI)                                               1 month
  CLARITY-TIMI 28 2005^30^   *Circulation*                                     1429/1431                                                    Retrospective analysis of randomised controlled trial (9/9)   Post-fibrinolysis PCI (STEMI)                                               1 month
  ASSENT-3 2003^32^          *Journal of the American College of Cardiology*   590/624                                                      Retrospective analysis of randomised controlled trial (9/9)   Post-fibrinolysis PCI (STEMI)                                               12 months
  ZEUS 2010^15^              *Eurointervention*                                436/440                                                      Randomised controlled trial (low risk)                        Elective or urgent PCI                                                      1 month
  Diez et al 2009^17^        *Texas Heart Institute Journal*                   222/271                                                      Registry (8/9)                                                Elective or urgent PCI                                                      In-hospital
  Zeymer et al 2006^20^      *American Journal of Cardiology*                  339/994                                                      Registry (8/9)                                                Early PCI                                                                   In-hospital
  STEEPLE 2006^11^           *New England Journal of Medicine*                 2298 (2 doses)/1230                                          Randomised controlled trial (low risk)                        Elective PCI                                                                1 month
  SYNERGY 2006^31^           *American Heart Journal*                          2028/2293                                                    Retrospective analysis of randomised controlled trial (9/9)   Elective or urgent PCI                                                      1 month
  Her et al 2006^21^         *Korean Circulation Journal*                      68/71                                                        Randomised controlled trial (unclear risk)                    Elective PCI                                                                1 month
  ACTION 2005^22^            *American Journal of Cardiology*                  100/100                                                      Randomised controlled trial (low risk)                        Elective PCI                                                                1 month
  CRUISE 2003^23^            *Journal of the American College of Cardiology*   129/132                                                      Randomised controlled trial (low risk)                        Elective or urgent PCI                                                      1 month
  Galeote et al 2002^24^     *Revista Espanola de Cardiologia*                 50/49                                                        Randomised controlled trial (unclear risk)                    Elective or urgent PCI                                                      In-hospital
  Drozd et al 2001^18^       *Kardiologia Polska*                              50/50                                                        Randomised controlled trial (unclear risk)                    Elective PCI                                                                1 month
  Dudek et al 2000^27^       *American Journal of Cardiology*                  200/200                                                      Randomised controlled trial (low risk)                        Elective or urgent PCI                                                      In-hospital
  Dudek et al 2000^26^       *Journal of the American College of Cardiology*   112 (2 doses)/50                                             Randomised controlled trial (unclear risk)                    Elective PCI                                                                In-hospital
  Rabah et al 1999^25^       *American Journal of Cardiology*                  30/30                                                        Randomised controlled trial (low risk)                        Elective PCI                                                                1 month

PCI=percutaneous coronary intervention; STEMI=ST elevation myocardial infarction.

\*Non-randomised controlled trials.

Summary of end points
---------------------

Figure 2[](#fig2){ref-type="fig"} summarises all studied end points for the total population of the meta-analysis, as well as the subgroup of patients undergoing primary percutaneous coronary intervention. The Cochrane P value for heterogeneity is included.

![**Fig 2** Pooled event rates and relative risk ratios for major end points in overall cohort of patients undergoing percutaneous coronary intervention (PCI) and in subgroup of patients undergoing primary percutaneous coronary intervention. STEMI=ST elevation myocardial infarction](silj003078.f2_default){#fig2}

Mortality
---------

In the overall cohort of patients (n=30 966), enoxaparin was associated with a 34% relative risk reduction (0.66, 95% confidence interval 0.58 to 0.77; P\<0.001) and a 1.66% absolute risk reduction of mortality (NNT=60; fig 3[](#fig3){ref-type="fig"}). Heterogeneity between trials was not significant (P=0.46) and evidence of publication bias using the funnel plot and Egger's regression test was lacking (P=0.82). In the higher risk group of patients with ST elevation myocardial infarction undergoing primary percutaneous coronary intervention (n=10 243), enoxaparin was associated with a significant 48% relative risk reduction in mortality (3.12% enoxaparin *v* 6.03% unfractionated heparin) and a 2.91% absolute relative risk reduction (P\<0.001; NNT=34). Heterogeneity between trials was not significant (P=0.53) and evidence of publication bias in the primary percutaneous coronary intervention subgroup was lacking (P=0.90). In the smaller and lower risk group of patients with non-ST elevation acute coronary syndromes and stable coronary artery disease undergoing scheduled percutaneous coronary intervention (relative weight 12.5%; mortality rate 0.88%) mortality rates did not differ significantly between the enoxaparin and unfractionated heparin cohorts, with a trend towards a reduction in mortality with enoxaparin.

![**Fig 3** All cause mortality in patients undergoing percutaneous coronary intervention (PCI) treated with enoxaparin or unfractionated heparin. STEMI=ST elevation myocardial infarction; non-STE ACS=non-ST elevation acute coronary syndrome](silj003078.f3_default){#fig3}

Safety outcomes
---------------

In the overall cohort of patients with reported major bleeding (n=30 775), enoxaparin was associated with a 20% relative risk reduction (0.80, 95% confidence interval 0.67 to 0.95; P=0.009) and an absolute risk reduction of 1.20% (NNT=83; fig 4[](#fig4){ref-type="fig"}). Heterogeneity between trials was not significant (P=0.58) and evidence of publication bias was lacking. The reduction in major bleeding seemed to be greater in patients with ST elevation myocardial infarction undergoing primary percutaneous coronary intervention, with enoxaparin treatment compared with unfractionated heparin treatment resulting in relative and absolute risk reductions of 28% and 1.9%, respectively (NNT=53), P=0.01.

![**Fig 4** Major bleeding in patients undergoing percutaneous coronary intervention (PCI) treated with enoxaparin or unfractionated heparin. STEMI=ST elevation myocardial infarction; non-STE ACS=non-ST elevation acute coronary syndrome](silj003078.f4_default){#fig4}

Although the incidence of minor bleeding was numerically lower in patients treated with enoxaparin than with unfractionated heparin, this difference was not significant in the overall percutaneous coronary intervention cohort or in the setting of primary percutaneous coronary intervention (fig 2).

Ischaemic end points
--------------------

Compared with unfractionated heparin, enoxaparin was associated with a 32% relative risk reduction and 2.01% absolute risk reduction of death or myocardial infarction (relative risk 0.68, 95% confidence interval 0.57 to 0.81; P\<0.001, NNT=50; see web extra figure 1). Similarly, enoxaparin was associated with a significant 25% relative risk reduction and 1.52% absolute risk reduction in complications of myocardial infarction (0.75, 0.66 to 0.85; P\<0.001; NNT=66; see web extra figure 2). Heterogeneity between trials for these two composite end points was not significant (P=0.42 and P=0.55, respectively) and evidence of publication bias using the funnel plot was not found.

The magnitude of the enoxaparin effect was largest in patients with ST elevation myocardial infarction undergoing primary percutaneous coronary intervention, with a 44% relative risk reduction and a 3.6% absolute risk reduction of death or myocardial infarction (0.56, 0.42 to 0.76; NNT=28; P\<0.001), with a consistent significant reduction of complications of myocardial infarction compared with unfractionated heparin (0.76, 0.60 to 0.96; P=0.022; see web extra figure 1).

Sensitivity and subgroups analyses
----------------------------------

A series of sensitivity analyses confirmed the same directionality for the primary efficacy end point (mortality) and the primary safety end point (major bleeding, tables 2[](#tbl2){ref-type="table"} and 3[](#tbl3){ref-type="table"}). None of the studies individually affected the overall results either for mortality or for major bleeding. The reduction in mortality associated with enoxaparin was consistent across all subgroups, with the single exception of the subgroup of small sized studies (\<500 patients), which showed a reduction of similar magnitude that did not reach significance (relative risk 0.59, 95% confidence interval 0.20 to 1.78; P=0.35). No subgroup analyses showed heterogeneity, and the superiority of enoxaparin on mortality was significant in both randomised controlled studies (n=16) and registry based studies (n=7). Results were consistent for major bleeding across all subgroups except for route of administered enoxaparin. In the subgroup of studies (14 studies, 10 260 patients) using intravenous enoxaparin, major bleeding was reduced by 34% compared with unfractionated heparin (0.66, 0.52 to 0.83; P\<0.001, P for heterogeneity 0.9; absolute risk reduction 1.52%; NNT=66). This favourable effect was not observed in the subgroup of studies that used subcutaneous enoxaparin (six studies, 16 527 patients), with no difference between the two anticoagulants (1.04, 0.80 to 1.35, P=0.7, P for heterogeneity 0.4). Finally, the arcsine test for binary outcomes confirmed the results of the primary additive summary models for all end points.

###### 

 Subgroup analysis for mortality

  Subgroup                          No of studies   No of patients   No of deaths/No in group   Relative risk (95% CI)   P values                        
  --------------------------------- --------------- ---------------- -------------------------- ------------------------ --------------------- --------- ------
  Overall                           23              30 966           278/13 943                 622/17 023               0.66 (0.57 to 0.76)   \<0.001   0.46
  Published (full length report)    21              30 404           278/13 631                 621/16 773               0.66 (0.56 to 0.77)   \<0.001   0.56
  Large size (≥500)                 12              28 778           275/12 852                 615/15 923               0.65 (0.52 to 0.81)   \<0.001   0.43
  Small size (\<500)                11              2188             3/1091                     7/1097                   0.59 (0.20 to 1.78)   0.35      0.46
  Patients with STEMI               10              18 993           237/7881                   557/11 112               0.62 (0.48 to 0.78)   \<0.001   0.52
  High quality studies: RCT\*       16              22 259           211/11 001                 325/11 258               0.78 (0.66 to 0.93)   0.006     0.97
  Low quality studies: registries   7               8707             67/2943                    297/5765                 0.43 (0.33 to 0.57)   \<0.001   0.86
  Subcutaneous enoxaparin           6†              16 527           197/7889                   314/8638                 0.70 (0.53 to 0.94)   0.017     0.57
  Intravenous enoxaparin            15†             10 451           74/5341                    151/5110                 0.66 (0.50 to 0.88)   0.004     0.99

STEMI=ST elevation myocardial infarction; RCT=randomised controlled trial.

\*Including substudies of RCTs.

†Two studies did not mention mode in which drug was administered.^20\ 33^

###### 

 Subgroup analysis for major bleeding

  Subgroup                              No of studies   No of patients   No with major bleeding/No in group   Relative risk (95%CI)   P values                        
  ------------------------------------- --------------- ---------------- ------------------------------------ ----------------------- --------------------- --------- ------
  Overall                               22\*            30 775           295/13 852                           564/16 923              0.80 (0.68 to 0.95)   0.009     0.58
  Published (full length report)        20              30 213           295/13 540                           564/16 673              0.80 (0.66 to 0.96)   0.022     0.62
  Large size (≥500)                     12              28 778           288/12 852                           549/15 926              0.80 (0.50 to 0.99)   0.041     0.55
  Small size (\<500)                    10              1997             7/1000                               15/997                  0.62 (0.27 to 1.42)   0.26      0.98
  Patients with STEMI                   9               18 802           170/7790                             384/11 012              0.80 (0.66 to 0.97)   0.026     0.44
  High quality studies: RCTs†           16              22 259           226/11 001                           299/11 258              0.83 (0.66 to 1.04)   0.11      0.70
  Low quality studies: registry based   7               8516             69/2851                              265/5665                0.73 (0.55 to 0.96)   0.026     0.80
  Subcutaneous enoxaparin               6               16 527           149/7889                             154/8638                1.04 (0.80 to 1.35)   0.75      0.43
  Intravenous enoxaparin                14              10 260           114/5250                             185/5010                0.66 (0.52 to 0.83)   \<0.001   0.90

RCT=randomised controlled trial; STEMI=ST elevation myocardial infarction.

\*One study did not report major bleeding in both groups and was excluded from analysis.^24^

Discussion
==========

In this meta-analysis, enoxaparin was superior to unfractionated heparin in reducing mortality and bleeding outcomes during percutaneous coronary intervention, particularly in patients undergoing primary percutaneous coronary intervention for ST elevation myocardial infarction. Since early 2000 data have accumulated on enoxaparin in varied percutaneous coronary intervention settings. This current meta-analysis, with information on more than 30 000 patients, showed a 34% statistically significant reduction in mortality (1.66% absolute risk reduction) in patients receiving enoxaparin during percutaneous coronary intervention compared with unfractionated heparin. This survival benefit is supported by concomitant reductions in both ischaemic and major bleeding complications. All sensitivity analyses of mortality confirmed a genuine difference between the two drugs. Subgroup analyses suggested that the benefits on mortality and ischaemic complications were largely driven by the superiority measured in patients undergoing primary percutaneous coronary intervention for ST elevation myocardial infarction, whereas the better safety outcomes might be driven by the intravenous (versus subcutaneous) use of enoxaparin.

This meta-analysis confirms the results recently reported in the ATOLL (Acute ST-elevation myocardial infarction Treated with primary angioplasty and intravenous enoxaparin Or unfractionated heparin to Lower ischemic and bleeding events at short- and Long-term follow-up) randomised trial.[@ref14] Compared with unfractionated heparin, intravenous enoxaparin at a dose of 0.5 mg/kg reduced death or resuscitated cardiac death in patients undergoing primary percutaneous coronary intervention by 42% (P=0.049) and death or myocardial infarction by 37% (P=0.02).[@ref14] Although the 40% relative risk reduction in all cause mortality associated with enoxaparin in ATOLL was not significant (P=0.08) owing to lack of power, it is consistent with the 38% reduction in mortality found in the group with ST elevation myocardial infarction in the current meta-analysis (P\<0.001), and more specifically with the 48% reduction of mortality in patients undergoing primary percutaneous coronary intervention (P\<0.001). The survival benefit associated with enoxaparin was present in both risk of bias subgroups in our meta-analysis; in low risk of bias studies (randomised trials and retrospective analysis of randomised trials) and in those showing higher risk of bias (non-randomised studies).

This reduction in mortality is likely to be related to the favourable effects of enoxaparin in the prevention of ischaemic complications, which were also shown in this meta-analysis. Consistent reductions in ischaemic end points were observed in the overall analysis as well as in the five largest randomised studies,[@ref13] [@ref14] [@ref30] [@ref35] [@ref42] which together represented two thirds of the weight of ischaemic events in our meta-analysis. In comparison with unfractionated heparin, enoxaparin has been shown to be more stable and have more predictable pharmacokinetics,[@ref1] providing an optimal level of anticoagulation at the time of the procedure in more than 90% of patients, by whatever route the drug is administered.[@ref9] [@ref49] [@ref50] [@ref51] These optimal levels of anticoagulation have also been related to better ischaemic and survival outcomes.[@ref10] Moreover, additional endothelial and anti-inflammatory properties of enoxaparin[@ref6] may play an additional part in the prevention of ischaemic complications of acute coronary syndrome.

Improved safety might also contribute to the reduction in mortality rates. Previous studies have shown that bleeding and red blood cell transfusion have deleterious effects[@ref52] and have an effect on ischaemic outcomes as well as on mortality.[@ref53] Therefore the 20% reduction in major bleeding associated with enoxaparin might also have affected ischaemic and mortality outcomes. This result is consistent among all subgroups, with the exception of studies in which subcutaneous enoxaparin was used in comparison with unfractionated heparin, when no difference was seen. It seems that the reduction in major bleeding was mostly observed with intravenous enoxaparin, but the P value for interaction was not significant probably because of the heterogeneity in risk levels of populations in the two subgroups (subcutaneous versus intravenous). Indeed, the intravenous route provides immediate anticoagulation, with rapid clearance,[@ref49] avoiding exposure to prolonged anticoagulation after percutaneous coronary intervention, and in this study was associated with a 34% reduction in major bleeding (absolute risk reduction 1.52%) compared with unfractionated heparin. Therefore this meta-analysis confirms the benefit of enoxaparin measured in the individual randomised STEEPLE[@ref1](elective angioplasty) and ATOLL[@ref14](primary angioplasty) studies, with enough power to show a reduction in mortality. Patients with ST elevation myocardial infarction obviously gain a large benefit from enoxaparin on ischaemic end points and mortality. Although favourable, the magnitude of these effects seems less important in other clinical situations.

Comparisons with other reviews
------------------------------

Other new anticoagulants have been compared with unfractionated heparin in the setting of percutaneous coronary intervention. Bivalirudin alone compared with unfractionated heparin plus glycoprotein IIb/IIIa inhibitors has consistently shown improved safety in percutaneous coronary intervention, associated with a reduction in mortality in one trial.[@ref54] [@ref55] [@ref56] [@ref57] Head to head comparisons of unfractionated heparin alone in percutaneous coronary intervention have also suggested a better safety profile of bivalirudin, but without significant advantage on the net clinical benefit or mortality.[@ref58] [@ref59] [@ref60] Finally, a recent meta-analysis of nine trials, totalling almost 30 000 patients, confirmed the reduction in major bleeding complications from use of bivalirudin compared with unfractionated heparin, but failed to show any benefit on mortality, whereas a trend for higher risk of myocardial infarction was noted.[@ref61] In contrast with this, a meta-analysis of nine studies, totalling 16 286 patients, comparing low molecular weight heparin with unfractionated heparin in the setting of percutaneous coronary intervention for ST elevation myocardial infarction reported a reduction in both mortality and major bleeding consistent with our findings.[@ref62]

An alternative anticoagulant, the synthetic factor Xa inhibitor fondaparinux, has been tested in acute coronary syndromes.[@ref63] Results were not favourable in patients with ST elevation myocardial infarction undergoing primary percutaneous coronary intervention[@ref64] and the drug has been tested only sparingly in elective percutaneous coronary intervention.[@ref65] A significant increase in catheter related thrombosis with fondaparinux prompted guidelines committees on both sides of the Atlantic to recommend unfractionated heparin as adjunctive treatment at the time of percutaneous coronary intervention. The recent results of the randomised Fondaparinux Trial With Unfractionated Heparin During Revascularization in Acute Coronary Syndromes (FUTURA) suggest that a standard unfractionated heparin dose of 85 IU/kg bolus, with an additional bolus if needed to achieve activated clotting time of 300 to 350 seconds, is preferable to a lower dose in patients previously treated with subcutaneous fondaparinux.[@ref3] In a pooled analysis of 19 085 patients with acute coronary syndrome invasively managed, fondaparinux reduced major bleeding compared with a heparin based strategy, with similar rates of ischaemic events and no reduction in mortality.[@ref66]

Strengths and limitations of this meta-analysis
-----------------------------------------------

Our meta-analysis has limitations and was not carried out on individual patients' data, which if possible would have strengthened the results, especially for subgroup analyses. Although differences in trial designs and definitions should be considered when interpreting the overall results, mortality is a hard end point not affected by study definitions. Duration and dose of study drugs also differed between trials, as did the use of concomitant treatments and types of revascularisation. Of note, many of the non-randomised studies were not pure head to head comparisons of the two anticoagulants. However, the absence of heterogeneity in the overall analysis and the sensitivity and subgroup analyses all showing consistent reductions in mortality, suggest that the results are robust. Regarding safety, it seems that the intravenous route for administering enoxaparin drives the reduction in major bleeding, confirming previous information from randomised trials.[@ref11] [@ref14] [@ref67] Duration of anticoagulation is a possible confounder for this problem, although this information is usually not available in published data.

Meaning of the study and implications for policymakers
------------------------------------------------------

The profound reduction in mortality found in this meta-analysis could be explained by the additional reductions of serious ischaemic events and major bleeding. The global reduction in ischaemic events and mortality was driven by the major effect observed in the setting of primary percutaneous coronary intervention for ST elevation myocardial infarction and is in line with the results of the ATOLL randomised trial.[@ref14] This effect was obtained from anticoagulation using intravenous enoxaparin and the favourable pharmacodynamic profile of the 0.5 mg/kg dose. A similar benefit on mortality has been seen recently in other studies of ST elevation myocardial infarction using bivalirudin[@ref56] or radial access.[@ref68] [@ref69] In lower risk populations the same interventions did not reduce mortality.[@ref1] [@ref54] [@ref69] The results of this meta-analysis should influence the next guidelines dealing with anticoagulation in percutaneous coronary intervention or in ST elevation myocardial infarction. The superiority of enoxaparin over unfractionated heparin is now well documented in the setting of percutaneous coronary intervention, by randomised controlled trials, registry based studies, and this meta-analysis, building the case for an update of current guidelines on anticoagulation. This is particularly true for primary percutaneous coronary intervention, where the benefit is most striking.

Unanswered questions and future research
----------------------------------------

Two new anticoagulants (bivalirudin and enoxaparin) have proved to be superior to unfractionated heparin during percutaneous coronary intervention, particularly in patients with ST elevation myocardial infarction undergoing primary percutaneous coronary intervention. A head to head comparison between intravenous enoxaparin and intravenous bivalirudin is needed in the setting of primary percutaneous coronary intervention using contemporary techniques (radial access, last generation of stent, and thromboaspiration) and new antiplatelet agents such as prasugrel or ticagrelor.

Conclusions
-----------

During percutaneous coronary intervention, enoxaparin seems to be superior to unfractionated heparin in reducing all cause mortality and ischaemic and bleeding end points. This superiority was particularly evident in patients with ST elevation myocardial infarction undergoing primary percutaneous coronary intervention. Given the relatively low cost of enoxaparin (and its wide availability), this seems to be an attractive strategy to improve outcomes in the large number of patients undergoing percutaneous coronary intervention worldwide.

### What is already known on this topic

1.  Enoxaparin has a more stable and predictable anticoagulant effect than unfractionated heparin, which requires tight monitoring and dose adjustment

2.  In randomised studies, intravenous enoxaparin 0.5 mg/kg was superior to unfractionated heparin in elective percutaneous coronary intervention (reduction of bleeding) and primary percutaneous coronary intervention (reduction of ischaemic events)

### What this study adds

1.  Enoxaparin use during percutaneous coronary intervention reduced mortality by 34% (absolute risk reduction 1.66%) compared with unfractionated heparin

2.  The mortality benefit was particularly noticeable in patients with ST elevation myocardial infarction undergoing primary percutaneous coronary intervention

3.  This survival benefit is supported by concomitant reductions in both ischaemic and major bleeding complications
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